Fluid bolus: Giving a fluid bolus of 500mL of normal saline (NaCl 0.9%)
Norepinephrine: brief, transient increase in norepinephrine to achieve a 15mmHg increase in mean arterial pressure and evaluates if tissue perfusion improves
Study summary
The goal of this observational study is to evaluate the reliability of the Argos system to track changes in cardiac output in critically ill patients. The main question it aims to answer is:
Does cardiac output changes induced by fluid administration or changes in norepinephrine dosage can be tracked by the Argos system, compared to transpulmonary thermodilution device.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age ≥18 years old
* Hospitalisation in intensive care
* Haemodynamic monitoring with transpulmonary thermodilution already in place
* Hemodynamic intervention deemed necessary by the clinician in charge of the patient
* Administration of a fluid bolus
* Change in norepinephrine dosage or performance of a vasopressor test
Exclusion Criteria:
* Pregnancy
* Other therapeutic modification during volume expansion or the vasopressor test
* Refusal to participate by relatives of the patient or the patient himself or herself
* Non availability of investigators
Primary outcome measure(s)
To compare the changes in cardiac output provided by the Argos system induced by changes in norepinephrine or fluid bolus, compared to cardiac output provided by the transpulmonary thermodilution device in critically ill patients. — 1 hour (before and after intervention)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
